COMMUNIQUÉS West-GlobeNewswire

Theratechnologies annonce la disponibilité d’EGRIFTA WR (MC) (tésamoréline) pour injection pour la réduction de l’excès de graisse abdominale chez les adultes vivant avec le VIH atteints de lipodystrophie
05/09/2025
EGRIFTA WR MC offre la commodité d’une reconstitution hebdomadaire et d’un volume d’injection quotidien réduit, comparativement à EGRIFTA SV MD Les pharmacies spécialisées commandent désormais EGRIFTA WR MC pour [...]
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
05/09/2025
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme replacement therapy ~ ~ Preliminary [...]
OrthoPediatrics Corp. Announces Distribution Agreement with MY01 Inc.
05/09/2025
Advancing Care for Pediatric Trauma Patients WARSAW, Ind., Sept. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics announced [...]
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
05/09/2025
-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- -- Announced in [...]
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
05/09/2025
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG [...]
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
05/09/2025
TORONTO and HOUSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage cancer immunotherapy company focused on the development of [...]
AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
05/09/2025
MILAN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation [...]
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
05/09/2025
BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer [...]
Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference
05/09/2025
LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor [...]
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/09/2025
BEDFORD, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention [...]
RHEA Essentials Inositol Returns for Hormonal Support
05/09/2025
VILNIUS, Lithuania, Sept. 05, 2025 (GLOBE NEWSWIRE) -- After months of being sold out, RHEA Essentials Inositol is finally returning, and people are already talking about it. Known for supporting hormonal balance, [...]
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
05/09/2025
COPENHAGEN, Denmark, September 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 3,818,710 as a consequence of employees’ exercise of warrants [...]
Tensive provides positive clinical updates highlighting potential of REGENERA™ / SOFTAG™ device to transform post-cancer breast reconstruction
05/09/2025
Clinical data from two ongoing trials in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits of device Primary safety and secondary performance objectives met in interim [...]
Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress
05/09/2025
The INFORM real-world evidence study shows impact of semaglutide on reducing ‘food noise’, and the STEP UP clinical trial highlights semaglutide’s effect on control of eating and body composition after losing weight [...]
Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension
05/09/2025
Multi-phase program to standardize treatment, generate real-world evidence and explore AI-powered tools to improve outcomes for hypertension patients Allschwil, Switzerland & Radnor, Philadelphia – September 5, 2025 [...]
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
05/09/2025
In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end 1 Over 60% of people with a [...]
MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy
05/09/2025
SAN JOSE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy [...]
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
05/09/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of [...]
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
05/09/2025
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study [...]

Pages